Related Experiment Video
Updated: Oct 9, 2025
08:01
Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management
Published on: November 30, 2022
4.8K
Biobank Participants' Attitudes toward Requiring Understanding for Biobank Consent.
T J Kasperbauer1, Colin Halverson2, Abigail Garcia3
1Postdoctoral fellow at the Indiana University Center for Bioethics at the Indiana University School of Medicine.
Ethics & Human Research
|December 22, 2021
Summary
Biobank participants prioritize helping research over fully understanding consent forms. They believe consent comprehension shouldn't gate enrollment, viewing biobank research as low risk.
Area of Science:
- Bioethics
- Informed Consent
- Biobanking Research Governance
Background:
- Biobank participants frequently exhibit limited understanding of informed consent information.
- Disagreements exist among ethicists and stakeholders regarding appropriate responses to comprehension deficits.
Purpose of the Study:
- To explore biobank enrollees' perspectives on the importance of understanding informed consent.
- To investigate whether comprehension levels should influence biobank enrollment eligibility.
Main Methods:
- Conducted knowledge tests with 22 recent biobank enrollees.
- Performed in-depth, semistructured interviews focusing on the goal of understanding in biobank consent.
Main Results:
- Enrollees considered knowledge test information important but opposed linking test performance to enrollment.
- Key themes: altruism in research contribution outweighs consent comprehension; lower understanding is acceptable due to low research risk; only essential information requires high comprehension.
Conclusions:
- Participant perspectives challenge stringent comprehension requirements for biobank consent.
- Findings necessitate consideration in ethical frameworks and governance models for biobanking.
- Future discussions on biobank consent should integrate participant views on risk, altruism, and essential information.
Related Concept Videos
01:15Bioavailability Study Design: Healthy Subjects Versus Patients
14
Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
14
01:56Ethics in Research
24.8K
Today, scientists agree that good research is ethical in nature and is guided by a basic respect for human dignity and safety. However, this has not always been the case. Modern researchers must demonstrate that the research they perform is ethically sound.
24.8K
01:13Bioequivalence studies: Biowaivers
11
Body:In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
11
01:23Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
196
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
196
01:16Bioequivalence: Overview
1.3K
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
1.3K
01:11Blinding
3.5K
Blinding is a commonly used method of not telling participants which treatment a subject is receiving. Blinding is a critical part of a randomized control trial or RCT. It reduces the bias that affects the results. In an RCT, blinding is used in the form of a placebo. A placebo effect occurs when untreated subjects falsely believe they have received the treatment and report improved symptoms. A placebo or a dummy treatment is administered to subjects to negate the bias caused by such an effect.
3.5K